

**Title:** Transcatheter Tricuspid Valve Replacement (TTVR)

**Decision:** The Centers for Medicare & Medicaid Services (CMS) established a National Coverage Determination (NCD) to cover transcatheter tricuspid valve replacement (TTVR) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED) when furnished according to a FDA market-authorized indication within a CMS-approved CED study. Nothing in this NCD would prevent coverage of TTVR through NCD 310.1 (Clinical Trial Policy) or through an Investigational Device Exemption (IDE) study.

**What this means:** Coverage of transcatheter tricuspid valve replacement (TTVR) for the treatment of symptomatic tricuspid regurgitation (TR) was previously subject to Medicare Administrative Contractor (MAC) local coverage determinations when applicable, or at the discretion of HealthPartners. TTVR for the treatment of symptomatic TR may now be covered for individuals who are enrolled in a CMS-approved study and who meet the criteria outlined in the Medicare NCD. Please refer to the final decision memo for all coverage criteria.

**Effective:** March 19, 2025

This announcement can be found at: [Transcatheter Tricuspid Valve Replacement \(TTVR\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2462\_90242 IR Approved 06/2015

H2422\_90242 IR Approved 07/2015

H4882\_90242 IR Approved 03/2018